Efficacy and tolerance of hyperthermic intravesical chemotherapy (HIVEC) according to the number of instillations administered.
BCG-unresponsive
Hyperthermic intravesical chemotherapy (HIVEC)
Non-muscle invasive bladder cancer (NMIBC)
Thermochemotherapy
Tolerance
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
received:
24
07
2024
accepted:
12
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
epublish
Résumé
To report the oncological outcomes and the tolerance between 6 instillations and more than 6 cycles of hyperthermic intravesical chemotherapy(HIVEC) in patients with non-muscle invasive bladder cancer(NMIBC). This is a multicenter retrospective study from a national database including 9 expert centers. All patients treated with HIVEC between 2016 and 2023 for NMIBC were included. Patients were classified into two groups according to the total number of HIVEC instillations, including induction plus maintenance. Kaplan-Meier curves were computed to present survival outcomes. 261 patients with a median follow-up of 25.5 months were included. 199(76.2%) and 62(23.8%) were treated by 6 and more than 6 cycles of HIVEC, respectively. The 2-years RFS(40.2% vs. 34.4%,p = 0.3) and the 2-years PFS(86% vs. 87%,p = 0.85) were similar between group treated with 6 and more than 6 instillations. 2-years CSS and OS were also similar between both groups. Univariate Cox regression showed no association between the number of bladder instillation and RFS (HR = 1.2 95%CI[0.8-1.84], p = 0.3) or PFS (HR = 0.8 95%CI[0.29-2.02], p = 0.2). In the group treated with more than 6 cycles, 2-years RFS and 2-years PFS were similar between patients who received induction plus maintenance compared to those treated with induction only. Finally, hematuria and urinary burning were significantly higher in the group treated by more than 6 cycles (21% vs. 8.5%(p < 0.01),and 29% vs. 17% (p = 0.03), respectively). Serious side effects(grade ≥ 3) are rare(3.1%) and similar in both groups. Results show no significant difference in two years RFS, PFS, CSS and OS according to number of instillations received, while toxicity profile seems better in the group receiving six instillations only.
Identifiants
pubmed: 39259376
doi: 10.1007/s00345-024-05219-3
pii: 10.1007/s00345-024-05219-3
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
516Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cancer today [cité 26 avr 2022]. Disponible sur: http://gco.iarc.fr/today/home
Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL et al (2022) European Association of Urology Guidelines on non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in situ). Eur Urol janv 81(1):75–94
doi: 10.1016/j.eururo.2021.08.010
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR et al (2016) Diagnosis and treatment of non-muscle invasive bladder Cancer: AUA/SUO Guideline. J Urol oct 196(4):1021–1029
doi: 10.1016/j.juro.2016.06.049
Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol mars 63(3):462–472
doi: 10.1016/j.eururo.2012.10.039
Maibom SL, Joensen UN, Poulsen AM, Kehlet H, Brasso K, Røder MA (2021) Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open Avr 11(4):e043266
doi: 10.1136/bmjopen-2020-043266
Syed S, Rahman M, Israr A, Anwar M, Khatroth S, Safi D et al (2023) A systematic review on the available treatment modalities for Bacillus Calmette-Guérin-unresponsive carcinoma in situ and tumors in patients who are ineligible for or decline radical cystectomy. SAGE Open Med 11:20503121231160410
doi: 10.1177/20503121231160408
Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F et al (2016) Results of a Randomised Controlled Trial comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for adjuvant treatment of patients with Intermediate- and high-risk non-muscle-invasive bladder Cancer. Eur Urol juin 69(6):1046–1052
doi: 10.1016/j.eururo.2016.01.006
Pignot G, Baboudjian M, Lebacle C, Chamouni A, Lechevallier E, Irani J et al (2023) Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. World J Urol Nov 41(11):3195–3203
doi: 10.1007/s00345-023-04332-z
Melgarejo Segura MT, Morales Martínez A, Yáñez Castillo Y, Arrabal Polo MÁ, Gómez Lechuga P, Pareja Vílchez M et al (2023) Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer. Urol Oncol févr 41(2):109.e1-109.e8.
van der Heijden AG, Verhaegh G, Jansen CFJ, Schalken JA, Witjes JA (2005) Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol avr 173(4):1375–1380
doi: 10.1097/01.ju.0000146274.85012.e1
Guerrero-Ramos F, González-Padilla DA, González-Díaz A, de la Rosa-Kehrmann F, Rodríguez-Antolín A, Inman BA et al (2022) Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol avr 40(4):999–1004
doi: 10.1007/s00345-022-03928-1
Plata A, Guerrero-Ramos F, Garcia C, González-Díaz A, Gonzalez-Valcárcel I, de la Morena JM et al (2021) Long-term experience with hyperthermic chemotherapy (HIVEC) using Mitomycin-C in patients with non-muscle invasive bladder Cancer in Spain. J Clin Med oct 10(21):5105
doi: 10.3390/jcm10215105
Brisuda A, Horňák J, Žemličková B, Háček J, Babjuk M (2024) Intravesical thermochemotherapy in the treatment of high-risk and very high-risk non-muscle-invasive urothelial bladder cancer: a single-arm study. Int Urol Nephrol. 8 févr
Magalhães JC, Sousa M, Basto R, Fraga T, Gomes I, Fernandes C et al (2023) Adjuvant hyperthermic intravesical chemotherapy in Intermediate- and high-risk non-muscle invasive bladder Cancer. Cureus Sept 15(9):e45672
Angulo JC, Álvarez-Ossorio JL, Domínguez-Escrig JL, Moyano JL, Sousa A, Fernández JM et al (2023) Hyperthermic Mitomycin C in Intermediate-risk non-muscle-invasive bladder Cancer: results of the HIVEC-1 trial. Eur Urol Oncol févr 6(1):58–66
doi: 10.1016/j.euo.2022.10.008
Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol mars 49(3):466–465
doi: 10.1016/j.eururo.2005.12.031
Tan WS, Panchal A, Buckley L, Devall AJ, Loubière LS, Pope AM et al (2019) Radiofrequency-induced Thermo-chemotherapy Effect Versus a second course of Bacillus Calmette-Guérin or institutional standard in patients with recurrence of non-muscle-invasive bladder Cancer following induction or maintenance Bacillus Calmette-Guérin therapy (HYMN): a phase III, Open-label, Randomised Controlled Trial. Eur Urol janv 75(1):63–71
doi: 10.1016/j.eururo.2018.09.005
Pijpers OM, Hendricksen K, Mostafid H, de Jong FC, Rosier M, Mayor N et al (2022) Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol. févr. ;40(2):62.e13-62.e20
Kiss B, Schneider S, Thalmann GN, Roth B (2015) Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? Int J Urol févr 22(2):158–162
doi: 10.1111/iju.12639
Thomsen JA, Nielsen Dominiak H, Lindgren MS, Jensen JB (2021) Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients. Scand J Urol août 55(4):281–286
doi: 10.1080/21681805.2021.1938664
de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL (2018) Hyperthermic Intravesical Chemotherapy for BCG unresponsive non-muscle invasive bladder Cancer patients. Bladder Cancer oct 4(4):395–401
doi: 10.3233/BLC-180191
Chiancone F, Fabiano M, Fedelini M, Meccariello C, Carrino M, Fedelini P (2020) Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. Cent Eur J Urol 73(3):287–294
Marquette T, Walz J, Rybikowski S, Maubon T, Branger N, Fakhfakh S et al (2020) [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG unresponsive non-muscle invasive bladder Cancer patients]. Prog Urol janv 30(1):35–40
doi: 10.1016/j.purol.2019.11.001